New Disease-Modifying Therapy Offers Hope for Early-Stage Alzheimer’s Patients, Per Advocate Group

New Disease-Modifying Therapy Offers Hope for Early-Stage Alzheimer’s Patients.

July 2, 2024 — The U.S. Food and Drug Administration (FDA) has approved Eli Lilly‘s (NYSE: LLY) Kisunla (donanemab), a new disease-modifying therapy for early-stage Alzheimer’s disease, marking a significant advancement in treatment options. UsAgainstAlzheimer’s welcomes this development as a beacon of hope for patients and their families.

Donanemab has demonstrated remarkable efficacy in removing brain plaque within months for most patients. This rapid action potentially allows some patients to discontinue the drug after a year or less, significantly reducing the long-term burden on both patients and caregivers.

George Vradenburg, chair and co-founder of UsAgainstAlzheimer’s, hailed the approval as a crucial milestone in the fight against Alzheimer’s. “This new therapy offers early-stage patients and their doctors a second choice for slowing disease progression,” Vradenburg stated. “The ability to potentially stop treatment after achieving results is a game-changer in Alzheimer’s care.”

The availability of a second treatment option for early-stage Alzheimer’s underscores the importance of early detection and accurate diagnosis. Vradenburg emphasized the need for annual cognitive screening programs to ensure timely intervention, stating, “It is time to adopt a program for annual cognitive screening to assure that Alzheimer’s is caught early and diagnosed accurately.”

This FDA approval not only provides patients with more treatment options but also offers the invaluable gift of time – potentially slowing the disease’s progression and maintaining quality of life for longer periods. 

As research continues and more therapies become available, early diagnosis and intervention will become increasingly crucial in the management of Alzheimer’s disease.

Eli Lilly’s Kinsula with square off against Biogen‘s Leqembi. The global Alzheimer’s disease market is estimated to grow to $8.18 billion by 2032, according to a report by Towards Healthcare.

A patient with Alzheimer's disease.

Subscribe

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BioMediaHub Logo